SCHEMBL14717415

SCHEMBL14717415

CC(C)Sc1ccc2nccc(Cl)c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.41
MET P08581 1/20 0.41
DYRK1B Q9Y463 1/20 0.38
NR4A2 P43354 2/20 0.37
AXL P30530 1/20 0.35
PRKCI P41743 1/20 0.35
CYP1A2 P05177 2/20 0.34
CYP2C19 P33261 2/20 0.34
LMNA P02545 1/20 0.34
HIF1A Q16665 1/20 0.34
KDM4E B2RXH2 2/20 0.33
MAPT P10636 2/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MEN1 O00255 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8603400 0.87 NR4A2 (0.40) NR4A2CYP1A2CYP2C19KDM4EMAPT
SCHEMBL17059462 0.82 SMN1; SMN2 (0.60) SMN1; SMN2CYP1A2CYP2C19LMNAHIF1A
SCHEMBL4015831 0.81 SMN1; SMN2 (0.44) SMN1; SMN2METDYRK1BNR4A2AXL
SCHEMBL30979525 0.81 SMN1; SMN2 (0.44) SMN1; SMN2METDYRK1BNR4A2AXL
SCHEMBL2594547 0.81 SMN1; SMN2 (0.41) SMN1; SMN2NR4A2CYP1A2CYP2C19LMNA
SCHEMBL17552281 0.78 SMN1; SMN2 (0.44) SMN1; SMN2METDYRK1BNR4A2AXL
SCHEMBL599549 0.77 SMN1; SMN2 (0.51) SMN1; SMN2METDYRK1BNR4A2AXL
SCHEMBL10119033 0.75 MET (0.39) SMN1; SMN2METDYRK1BNR4A2AXL
SCHEMBL27465843 0.75 MET (0.39) SMN1; SMN2METDYRK1BNR4A2AXL
SCHEMBL11729538 0.75 DYRK1B (0.40) SMN1; SMN2DYRK1BNR4A2AXLPRKCI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160060222-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC 2016-03-03 US disclosed
EP-2566477-B1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2015-09-02 EP disclosed
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060222-A1 AMINO-QUINOLINES AS KINASE INHIBITORS ABL1, MAP3K2, MAP4K2 SMN1; SMN2 4200/4885MET 631/4885DYRK1B 419/4885
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS ABL1, MAP3K2, MAP4K2 SMN1; SMN2 4200/4885MET 631/4885DYRK1B 419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.